Navigation Links
Telik Announces Publication of a Case Report of a Sustained Hematologic Response in Myelodysplastic Syndrome Following an Abbreviated Exposure to Oral Telintra(R) (Ezatiostat HCl)
Date:6/21/2010

od transfusions to manage their disease.

There remains a critical need for effective, well tolerated therapies for MDS.  Telintra has a novel mechanism of action that inhibits an enzyme called glutathione S-transferase P1-1 which may activate JNK kinase, a key regulator of cellular growth and differentiation of blood precursor cells.  Telintra has been shown to stimulate normal multilineage differentiation of blood stem cell precursors and induce cancer cell death, or apoptosis, in human leukemia cell lines.  Additional information on Telintra is available at www.telik.com

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidates in clinical development are Telintra, a modified glutathione analog for the treatment of MDS and Severe Chronic Neutropenia (SCN), and Telcyta® a cancer activated prodrug for the treatment of advanced non-small cell lung cancer and ovarian cancer.  Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

This press release contains "forward looking" statements regarding the future development of Telintra, the effectiveness of Telintra in treating MDS alone and in combination or following treatment with other drugs, whether Telintra treatment results in hematologic improvement in patients with MDS or offers an alternative to RBC blood transfusions, other potential
'/>"/>

SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
2. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
3. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
4. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
5. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
6. Telik Announces Presentation at ASCO Annual Meeting
7. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
8. Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
9. Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
10. Telik Announces Third Quarter 2009 Financial Results
11. Telik Announces Fourth Quarter and 2009 Year End Financial Results and 2010 Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... NEWTON, Mass. and JERUSALEM ... privately-held biopharma company developing octreotide capsules, its lead product ... of a $70 million Series E financing round. Participants ... and Sofinnova Ventures, and an undisclosed blue chip public ... F2 Capital, 7 Med Health Ventures, Abingworth and ARCH ...
(Date:2/26/2015)... , Feb. 27, 2015  Finesse expands office in ... Solutions announced the expansion of its operations in ... for mid-March and access for customers is expected shortly ... and located adjacent to the current office, the new ... engineering team and allow Finesse to bring on more ...
(Date:2/26/2015)... , Feb. 26, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ Insulin ... offering of 5,250,000 shares of its common stock at ... The net proceeds to Tandem from this offering are ... and commissions and other estimated offering expenses payable by ...
Breaking Medicine Technology:Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3New Finesse Office in United Kingdom 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3
... published in the American Journal of Nephrology -, ... announced that its Phase III data on VAPRISOL was ... Nephrology. In this study,VAPRISOL showed a significant increase in ... life-threatening condition that,occurs when the body,s sodium level falls ...
... Cancer patients at Beaumont,Hospitals are the first in the ... therapy that is painless, faster, more accurate and precise,than ... patented the new,technology, Omnibeam(R). The $3.3-million machine is manufactured ... first patient,was treated on Sept. 10. The painless ...
Cached Medicine Technology:Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 2Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 3Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 4Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 5Beaumont Patients 1st to get Next Generation of Radiation Treatment 2
(Date:2/27/2015)... (PRWEB) February 27, 2015 According to ... in the China Dental Industry in 2013 rose by ... the total amount of revenue generated by the industry ... that was registered by the industry in 2013. ... The report has identified the oral industry as a ...
(Date:2/27/2015)... 2015 Several studies showing the promise ... have made headline news recently. However, all these studies ... in this month’s STEM CELLS Translational Medicine shows that ... children with congenital heart diseases that can lead to ... at the Mayo Clinic in Rochester, Minn., looked at ...
(Date:2/27/2015)... 2015 Ticket Down announces that Ed ... summer months of 2015. Tickets for his tour have ... at a record pace. , Ed Sheeran 2015 ... Erwin Center, Wednesday, May 6, 2015 , 5/7/15, Ed Sheeran ... May 7, 2015 , 5/9/15, Ed Sheeran Tickets, Tulsa, OK ...
(Date:2/27/2015)... 27, 2015 Burien Nursing and ... Health Care, Inc. with the Facility of the ... four key areas: Outstanding quality of care / satisfaction, ... Lynda Baldwin was invited to attend the awards banquet ... “I am delighted to receive this award on behalf ...
(Date:2/27/2015)... RDI-Engineering will be hosting an educational ... on March 14, at Moreno Valley College. The station ... to use engineering software and tools, and a few ... Moreno Valley College’s Upward Bound Math and Science (UBMS) ... hopes to encourage students to seek educational and career ...
Breaking Medicine News(10 mins):Health News:China Dental Industry to Expand Rapidly Owing to the Evolution of Medical and Healthcare Systems: MarketResearchReports.Biz 2Health News:China Dental Industry to Expand Rapidly Owing to the Evolution of Medical and Healthcare Systems: MarketResearchReports.Biz 3Health News:Study Shows Stem Cells Have Potential to Help Kids’ Hearts, Too 2Health News:Ed Sheeran Tickets at the Hollywood Bowl, Verizon Theatre, The Mann Center, Darlings Waterfront Pavilion, Moda Center, BOK Center, Consol Energy & Red Rocks Now On Sale 2Health News:Ed Sheeran Tickets at the Hollywood Bowl, Verizon Theatre, The Mann Center, Darlings Waterfront Pavilion, Moda Center, BOK Center, Consol Energy & Red Rocks Now On Sale 3Health News:Ed Sheeran Tickets at the Hollywood Bowl, Verizon Theatre, The Mann Center, Darlings Waterfront Pavilion, Moda Center, BOK Center, Consol Energy & Red Rocks Now On Sale 4Health News:Burien Nursing and Rehabilitation Center Receives Top Honors with Facility of the Year Award 2Health News:Burien Nursing and Rehabilitation Center Receives Top Honors with Facility of the Year Award 3Health News:RDI-Engineering Participates in STEM”U”LATE Your Mind Event to Host Educational Exhibition 2
... , NASHVILLE, Tenn. , Jan. 26 ... announced that on Monday evening, February 22, 2010 , after ... of 2009.   , On February 23, 2010 , at ... a conference call to discuss earnings results, quarterly activities, general operations ...
... , , OAKLAND, Calif. , ... union election results for Kaiser Permanente nurses, psych-social ... Trossman , communications director of the Service Employees ... statement: , "While today,s election results are disappointing, ...
... Jan. 26 Yesterday, Randall Terry , who is regrettably ... news release, "We are not coming to condone or condemn Scott ... figure John Brown . , The Advisory Board of Operation Rescue ... violence. , "The Board of Operation Rescue wants to make it clear ...
... CLEVELAND , Jan. 26 The Cleveland ... will host a panel discussion Feb. 18 addressing ... http://www.newscom.com/cgi-bin/prnh/20070517/IABCLOGO ) , Health care communication leaders from ... care reform, public option, social media and more are impacting ...
... , BALTIMORE , Jan. 26 Lutheran World ... has arrived safely. , "Our partners at Church World Service ... immediately to the people who need it," says Trevor Knoblich ... jointly by LWR and CWS, contained health kits and layettes from ...
... , COLUMBUS, Ohio , Jan. 26 ... of Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL) 30mL and 120mL ... and Drug Administration. This product is indicated for the relief of ... opioid analgesic is appropriate. , Roxane Laboratories, Inc. Morphine Sulfate Oral ...
Cached Medicine News:Health News:Healthcare Realty Trust Announces Fourth Quarter Earnings Release Date and Conference Call 2Health News:SEIU-UHW Statement on Kaiser Union Election in Southern California 2Health News:Operation Rescue's Advisory Board Issues Statement on Mr. Terry's Extremism 2Health News:IABC Cleveland Presents 'The Changing Face of Health Care Communications' at Feb. 18 Luncheon 2Health News:LWR Health Kits, Layettes Arrive in Haiti as Relief Efforts Ramp Up 2Health News:LWR Health Kits, Layettes Arrive in Haiti as Relief Efforts Ramp Up 3Health News:Roxane Laboratories, Inc. Announces the New Drug Application Approval of Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL) 2Health News:Roxane Laboratories, Inc. Announces the New Drug Application Approval of Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL) 3
Flexible rake retractor, 3 blunt prongs....
Rees bayonet forceps, standard, 5-1/2", TC....
... Implants, designed to accept rigid ... with an excellent reconstructive option ... floor blowout defects. Each design ... of one or more rigid ...
... Medpor Midface Rim is designed ... concavities of the midface, including ... malar. When positioned in the ... Medpor Midface Rim implant aids ...
Medicine Products: